
ESR1 Inhibitors: Transforming Breast Cancer Care
The evolving landscape of breast cancer treatment emphasizes the pivotal role of ESR1 inhibitors in combating endocrine resistance. Targeting mutations in ER-positive breast cancer, key inhibitors, like camizestrant and elacestrant, show promising results in extending progression-free survival. Precision diagnostics and strategic treatments reveal the transformative potential of therapies in patient outcomes. Understand insights into crucial […]
3 minute read